
Using an implantable device, a UH team demonstrated that systolic blood pressure can be lowered 10% in one hour and 16% two hours after nerve stimulation.
Using Newly Developed Mini Electrodes to Fight Hypertension
A University of Houston biomedical engineer is expanding the study of wireless electrodes to treat hypertension and is reporting that blood pressure and renal sympathetic nerve activity (RSNA) is controlled by bioelectronic treatment. RSNA is often increased in hypertension and renal disease.
Using a custom-wired electrode, Mario Romero-Ortega, Cullen Endowed Professor of biomedical engineering, previously reported that deep peroneal nerve stimulation (DPNS) elicits an acute reduction in blood pressure. The current study, published in Frontiers in Neuroscience,advances that work, focusing on his development of a small implantable wireless neural stimulation system and exploration of different stimulation parameters to achieve a maximum lowered response.
Romero-Ortega integrated a sub-millimeter nerve stimulation circuit with a novel nerve attachment microchannel electrode that facilitates implantation into small nerves and allows external power and DPNS modulation control.
Using this implantable device, his team demonstrated that systolic blood pressure can be lowered 10% in one hour and 16% two hours after nerve stimulation.
“Our results indicate that DPNS consistently induces an immediate and reproducible arterial depressor effect in response to electrical stimulation of the deep peroneal nerve,” reports Romero-Ortega.
Hypertension, often called the ‘silent killer’ speaks loudly in statistics. In the United States, it is the number one cause of death. Globally it is the number one risk factor for death, impacting more than 1 billion people and is to blame for about half of all stroke and heart related deaths. The American College of Cardiology/American Heart Association 2018 guidelines classified average systolic blood pressure as greater than 130 mmHg and diastolic BP greater than 80 mmHg, on at least two separate occasions, as hypertension.
While pharmacological treatments are effective, blood pressure remains uncontrolled in 50–60% of resistant hypertensive subjects. Unfortunately, despite the use of multiple antihypertensive drugs in combination, blood pressure remains poorly controlled in 50–60% of the hypertensive population and approximately 12–18% of them develop resistant hypertension, defined as blood pressure greater than 140/90 mmHg despite the use of antihypertensive drugs.
In this study, DPNS induced an initial increase in RSNA during the first 2–3 seconds, followed by a reduction in renal activity and mean arterial pressure, despite the increase in heart rate,” said Romero-Ortega. The observed activation of the RSNA during the DPNS was not expected since its activity is associated with hypertension.”
Original Article: Deep Nerve Stimulation Consistently Reduces Blood Pressure
More from: University of Houston
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Deep nerve stimulation
- Neuromodulation Devices Global Market - Forecast To 2029
Neuromodulation treatment involves direct stimulation or modulation of the nerves by an electrical or magnetic field. It is used as a treatment for unmanageable chronic pain, movement disorders, ...
- Vagus Nerve Stimulation Devices Market : Industry Analysis 2023 To 2028 based on Sales, Revenue, Size and Share
Vagus Nerve Stimulation Devices Market Size is projected to Reach Multimillion USD by 2029, In comparison to 2022, ...
- YOUR HEALTH: Spinal stimulator stops diabetic nerve pain
Thirty-seven million Americans have diabetes, a condition where your body doesn’t make insulin or doesn’t use it well.
- Can Vagus Nerve Stimulation Treat Stroke?
In fact, the “breakthrough” nomenclature comes courtesy of FDA, which granted the Vivistim System Breakthrough Device Designation and then pre-market device approval for its Vivistim Paired VNS vagus ...
- Research finds if brain and nerve stimulation help persons with spinal cord injury
In animal trials, a nerve stimulation technique developed at the Vagelos College of Physicians and Surgeons at Columbia University is showing promise and may someday help people with spinal cord ...
Go deeper with Google Headlines on:
Deep nerve stimulation
[google_news title=”” keyword=”deep nerve stimulation” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Hypertension
- 'Flashdance' singer Irene Cara, 63, dies from hypertension, high cholesterol — who's at risk?
Irene Cara's cause of death has been revealed and the Heart & Stroke foundation has deemed it a significant issue in Canada.
- Pulmonary Arterial Hypertension (PAH) Drugs Global Market 2022: Sector to Reach $9.4 Billion by 2027 at a CAGR of 5.29%
DUBLIN, Feb. 3, 2023 /PRNewswire/ -- The "Pulmonary Arterial Hypertension (PAH) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
- Indian needs a new healthcare model to effectively manage hypertension
Success will help in reducing government spending for the poor battling the cost of treating non-communicable diseases ...
- Irene Cara's cause of death revealed as hypertension and high cholesterol
Irene Cara's cause of death has been revealed to be hypertension and high cholesterol. According to documents from the medical examiner in Florida's Pinellas County, the Fame star's cause of death has ...
- 'Flashdance' Singer Irene Cara Died of Hypertension, High Cholesterol: Report
The cause of death for "Fame" and "Flashdance" singer Irene Cara has been revealed. The star, 63, died of hypertension and high cholesterol, with her official cause of death listed as arteriosclerotic ...
Go deeper with Google Headlines on:
Hypertension
[google_news title=”” keyword=”circular fuel economy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]